Abstract
AbstractCell-free DNA (cfDNA) sequencing has demonstrated great potential for early cancer detection. However, most large-scale studies have focused only on either targeted methylation sites or whole-genome sequencing, limiting comprehensive analysis that integrates both epigenetic and genetic signatures. In this study, we present a platform that enables simultaneous analysis of whole-genome methylation, copy number, and fragmentomic patterns of cfDNA in a single assay. Using a total of 950 plasma (361 healthy and 589 cancer) and 240 tissue samples, we demonstrate that a multifeature cancer signature ensemble (CSE) classifier integrating all features outperforms single-feature classifiers. At 95.2% specificity, the cancer detection sensitivity with methylation, copy number, and fragmentomic models was 77.2%, 61.4%, and 60.5%, respectively, but sensitivity was significantly increased to 88.9% with the CSE classifier (p value < 0.0001). For tissue of origin, the CSE classifier enhanced the accuracy beyond the methylation classifier, from 74.3% to 76.4%. Overall, this work proves the utility of a signature ensemble integrating epigenetic and genetic information for accurate cancer detection.
Funder
National Research Foundation of Korea
Publisher
Springer Science and Business Media LLC
Subject
Clinical Biochemistry,Molecular Biology,Molecular Medicine,Biochemistry
Reference72 articles.
1. World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer (2021).
2. National Cancer Center. National Cancer Screening Program. https://ncc.re.kr/main.ncc?uri=english/sub04_ControlPrograms03 (2016).
3. Smith, R. A. et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin. 69, 184–210 (2019).
4. Crosby, D. et al. Early detection of cancer. Science 375, eaay9040 (2022).
5. Gao, Q. et al. Circulating cell-free DNA for cancer early detection. Innovation 3, 100259 (2022).